Table 1.
Patient characteristics, co-morbidities, and venous thrombo-embolism therapy
| Total (n= 1247) | Age ≥65 (n= 644) | Age <65 (n= 603) | P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years), mean ± SD | 61 ± 18 | 76 ± 7 | 46 ± 13 | <0.001 |
| Women, n (%) | 605 (48.5) | 321 (49.8) | 284 (47.1) | 0.33 |
| Inpatient at the time of diagnosis, n (%) | 478 (38.3) | 304 (47.2) | 174 (28.9) | <0.001 |
| Prior hospitalization, n (%) | 332 (26.6) | 179 (27.8) | 153 (25.4) | 0.33 |
| Co-morbidities | ||||
| Cancer, n (%) | 315 (25.3) | 192 (29.8) | 123 (20.4) | <0.001 |
| Metastatic disease, n (%) | 179 (65.1) | 97 (59.9) | 82 (72.6) | 0.030 |
| Recent cancer surgery, n (%) | 83 (27.8) | 37 (20.9) | 46 (37.7) | 0.001 |
| Recent chemotherapy, n (%) | 154 (52.2) | 77 (44.0) | 77 (64.2) | 0.001 |
| Prior VTE, n (%) | 288 (23.1) | 147 (22.8) | 141 (23.4) | 0.82 |
| Bed rest for >3 days, n (%) | 231 (18.5) | 146 (22.7) | 85 (14.1) | <0.001 |
| Obesity, n (%) | 174 (14.0) | 76 (11.8) | 98 (16.3) | 0.023 |
| Surgery, n (%) | 170 (13.6) | 74 (11.5) | 96 (15.9) | 0.023 |
| Varicosis, n (%) | 164 (13.2) | 102 (15.8) | 62 (10.3) | 0.004 |
| Acute infection/sepsis n (%) | 148 (11.9) | 92 (14.3) | 56 (9.3) | 0.006 |
| Chronic lung disease, n (%) | 140 (11.2) | 91 (14.1) | 49 (8.1) | 0.001 |
| Diabetes, n (%) | 114 (9.1) | 90 (14.0) | 24 (4.0) | <0.001 |
| Ongoing chemotherapy, n (%) | 114 (9.1) | 59 (9.2) | 55 (9.1) | 0.98 |
| Trauma/fracture n (%) | 91 (7.3) | 34 (5.3) | 57 (9.5) | 0.005 |
| Renal failure, n (%) | 89 (7.1) | 61 (9.5) | 28 (4.6) | 0.001 |
| Inflammatory/rheumatic disease, n (%) | 89 (7.1) | 50 (7.8) | 39 (6.5) | 0.37 |
| Acute respiratory failure, n (%) | 83 (6.7) | 59 (9.2) | 24 (4.0) | <0.001 |
| Congestive heart failure, n (%) | 81 (6.5) | 71 (11.0) | 10 (1.7) | <0.001 |
| ICU admission, n (%) | 69 (5.5) | 41 (6.4) | 28 (4.6) | 0.18 |
| History of stroke/TIA, n (%) | 67 (5.4) | 61 (9.5) | 6 (1.0) | <0.001 |
| Bleeding requiring treatment within 30 days prior to VTE diagnosis, n (%) | 60 (4.8) | 34 (5.3) | 26 (4.3) | 0.43 |
| Acute heart failure, n (%) | 37 (3.0) | 31 (4.8) | 6 (1.0) | <0.001 |
| VTE therapy | ||||
| Inpatient therapy, n (%) | 800 (64.2) | 484 (75.2) | 316 (52.4) | <0.001 |
| Compression therapy, n (%) | 1'031 (82.7) | 548 (85.1) | 483 (80.1) | 0.020 |
| IVC filter, n (%) | 20 (1.6) | 12 (1.9) | 8 (1.3) | 0.45 |
| UFH or LMWH, n (%) | 1'200 (96.2) | 619 (96.1) | 581 (96.4) | 0.83 |
| Vitamin K antagonist, n (%) | 970 (77.8) | 509 (79.0) | 461 (76.5) | 0.27 |
| Planned duration of anticoagulation | ||||
| ≤3 months, n (%) | 198 (15.9) | 85 (13.2) | 113 (18.7) | 0.007 |
| >3–6 months, n (%) | 483 (38.7) | 237 (36.8) | 246 (40.8) | 0.15 |
| >6–12 months, n (%) | 243 (19.5) | 128 (19.9) | 115 (19.1) | 0.72 |
| >12 months or indefinitely, n (%) | 323 (25.9) | 194 (30.1) | 129 (21.4) | <0.001 |
VTE, venous thrombo-embolism; ICU, intensive care unit; TIA, transient ischemic attack; IVC, inferior vena cava; UFH, unfractionated heparin; LMWH, low-molecular-weight heparin.